NL-OMON34533已完成3 期
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients with Episodic Migraine - MK0974-065
Merck Sharp & Dohme (MSD)0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. patient is >=18 years of age at screening.
- •2. female who has regular menstrual cycles monthly (22 to 32 days) for at least the last 3 cycles.
- •3. history of migraine with or without aura for >=3 months and with >=2 migraine attacks per month in te 2 months prior to screening.
- •4. headache during menstrual period in at least 2 out of last 3 cycles.
排除标准
- •1. patient has basilar or hemiplegic migraine headache. 2. patient has taken medication for acute headache atttack on more than 15 days per month in any of the 3 months prior to screening. 3. patient is taking migraine prophylactic medication where the prescribed daily dose has changed during the 4 weeks prior to screening. 4. history of liver disease. 5. consumes 3 or more alcoholic drinks per day.
研究者
相似试验
进行中（未招募）
不适用
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients with Episodic Migraine - MK0974-065MedDRA version: 12.1Level: LLTClassification code 10027599Term: MigraineMigraineEUCTR2010-019288-13-NLMerck, Sharp & Dohme B.V.4,500
进行中（未招募）
不适用
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients with Episodic MigraineMedDRA version: 12.1Level: LLTClassification code 10027599Term: MigraineMigraineEUCTR2010-019288-13-SEMSD4,500
进行中（未招募）
不适用
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerabitlity, and Efficacy of Telcagepant (MK-0974) for prevention of Menstrually Related Migraine in Female Patients with Episodic MigraineMigraineEUCTR2010-019288-13-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.4,500
进行中（未招募）
不适用
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients with Episodic MigraineMigraineEUCTR2010-019288-13-DKMerck Sharp & Dohme Corp.4,500
进行中（未招募）
不适用
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients with Episodic MigraineMedDRA version: 12.1Level: LLTClassification code 10027599Term: MigraineMigraineEUCTR2010-019288-13-GBMerck Sharp & Dohme Corp.4,500